JAIDS Study by Argos Therapeutics, Inc. Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients

Published: Sep 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its dendritic cell-based immunotherapy, AGS-004 in the treatment of HIV-infected patients receiving antiretroviral therapy (ART). The study confirmed that antiviral cytotoxic T-cell immunity can be induced in HIV infected patients without being accompanied by generalized systemic immune activation.

Help employers find you! Check out all the jobs and post your resume.

Back to news